Lee's Pharmaceutical Holdings Limited (0950.HK)
HKD 1.3
(6.56%)
HKD 1.3
(6.56%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 36.04 Million HKD | -132.26% |
| 2022 | 123.01 Million HKD | 17826.08% |
| 2021 | -694 Thousand HKD | -100.46% |
| 2020 | 151.92 Million HKD | -37.89% |
| 2019 | 244.59 Million HKD | -47.62% |
| 2018 | 466.93 Million HKD | 68.67% |
| 2017 | 276.82 Million HKD | -7.24% |
| 2016 | 298.42 Million HKD | 4.19% |
| 2015 | 286.42 Million HKD | 23.73% |
| 2014 | 231.49 Million HKD | 28.35% |
| 2013 | 180.36 Million HKD | 34.24% |
| 2012 | 134.36 Million HKD | 36.0% |
| 2011 | 98.79 Million HKD | 40.77% |
| 2010 | 70.17 Million HKD | 31.24% |
| 2009 | 53.47 Million HKD | 72.01% |
| 2008 | 31.08 Million HKD | 127.27% |
| 2007 | 13.67 Million HKD | 610.95% |
| 2006 | -2.67 Million HKD | -582.34% |
| 2005 | 555 Thousand HKD | 120.23% |
| 2004 | -2.74 Million HKD | 43.16% |
| 2003 | -4.82 Million HKD | -0.86% |
| 2002 | -4.78 Million HKD | -139.49% |
| 2001 | -1.99 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q4 | 1.81 Million HKD | 0.0% |
| 2023 Q2 | 16.2 Million HKD | 0.0% |
| 2023 Q1 | 16.2 Million HKD | 148.33% |
| 2023 FY | -39.68 Million HKD | -132.26% |
| 2023 Q3 | 1.81 Million HKD | -88.78% |
| 2022 Q4 | -33.52 Million HKD | -161.78% |
| 2022 Q1 | 35.5 Million HKD | 120.13% |
| 2022 Q2 | 20.31 Million HKD | -42.77% |
| 2022 Q3 | 54.26 Million HKD | 167.1% |
| 2022 FY | 123.01 Million HKD | 17826.08% |
| 2021 Q2 | 2.09 Billion HKD | 4324.58% |
| 2021 Q4 | -176.38 Million HKD | -1587.62% |
| 2021 FY | -694 Thousand HKD | -100.46% |
| 2021 Q3 | 11.85 Million HKD | -99.43% |
| 2021 Q1 | 47.36 Million HKD | 181.57% |
| 2020 FY | 151.92 Million HKD | -37.89% |
| 2020 Q1 | 50.03 Million HKD | -24.08% |
| 2020 Q2 | 64.8 Million HKD | 29.52% |
| 2020 Q3 | 20.25 Million HKD | -68.74% |
| 2020 Q4 | 16.82 Million HKD | -16.97% |
| 2019 FY | 244.59 Million HKD | -47.62% |
| 2019 Q3 | 45.02 Million HKD | 233.44% |
| 2019 Q4 | 65.9 Million HKD | 46.38% |
| 2019 Q1 | 64.22 Million HKD | -70.16% |
| 2019 Q2 | -33.74 Million HKD | -152.54% |
| 2018 Q4 | 215.18 Million HKD | 139.9% |
| 2018 Q2 | 74.97 Million HKD | -13.91% |
| 2018 Q1 | 87.08 Million HKD | 19.16% |
| 2018 FY | 466.93 Million HKD | 68.67% |
| 2018 Q3 | 89.69 Million HKD | 19.64% |
| 2017 Q2 | 69.64 Million HKD | 27.71% |
| 2017 Q1 | 54.53 Million HKD | -26.02% |
| 2017 FY | 276.82 Million HKD | -7.24% |
| 2017 Q3 | 79.56 Million HKD | 14.23% |
| 2017 Q4 | 73.08 Million HKD | -8.14% |
| 2016 Q4 | 73.71 Million HKD | -12.4% |
| 2016 Q3 | 84.15 Million HKD | 8.19% |
| 2016 Q1 | 62.78 Million HKD | -7.87% |
| 2016 Q2 | 77.78 Million HKD | 23.89% |
| 2016 FY | 298.42 Million HKD | 4.19% |
| 2015 FY | 286.42 Million HKD | 23.73% |
| 2015 Q3 | 75.74 Million HKD | -22.48% |
| 2015 Q2 | 97.71 Million HKD | 118.01% |
| 2015 Q1 | 44.82 Million HKD | -32.45% |
| 2015 Q4 | 68.14 Million HKD | -10.04% |
| 2014 Q2 | 53.42 Million HKD | 1.1% |
| 2014 Q3 | 58.87 Million HKD | 10.19% |
| 2014 Q4 | 66.34 Million HKD | 12.69% |
| 2014 FY | 231.49 Million HKD | 28.35% |
| 2014 Q1 | 52.84 Million HKD | 11.97% |
| 2013 Q2 | 48.85 Million HKD | 28.28% |
| 2013 Q3 | 46.22 Million HKD | -5.38% |
| 2013 Q4 | 47.19 Million HKD | 2.1% |
| 2013 FY | 180.36 Million HKD | 34.24% |
| 2013 Q1 | 38.08 Million HKD | 10.51% |
| 2012 FY | 134.36 Million HKD | 36.0% |
| 2012 Q3 | 36.06 Million HKD | 3.52% |
| 2012 Q1 | 28.98 Million HKD | -10.7% |
| 2012 Q2 | 34.84 Million HKD | 20.19% |
| 2012 Q4 | 34.46 Million HKD | -4.45% |
| 2011 Q1 | 19.34 Million HKD | 0.0% |
| 2011 Q4 | 32.46 Million HKD | 16.72% |
| 2011 FY | 98.79 Million HKD | 40.77% |
| 2011 Q2 | 19.18 Million HKD | -0.83% |
| 2011 Q3 | 27.81 Million HKD | 44.99% |
| 2010 FY | 70.17 Million HKD | 31.24% |
| 2010 Q2 | 18.86 Million HKD | 0.0% |
| 2009 Q2 | 13.75 Million HKD | 0.0% |
| 2009 FY | 53.47 Million HKD | 72.01% |
| 2008 FY | 31.08 Million HKD | 127.27% |
| 2007 FY | 13.67 Million HKD | 610.95% |
| 2006 FY | -2.67 Million HKD | -582.34% |
| 2005 FY | 555 Thousand HKD | 120.23% |
| 2004 FY | -2.74 Million HKD | 43.16% |
| 2003 FY | -4.82 Million HKD | -0.86% |
| 2002 FY | -4.78 Million HKD | -139.49% |
| 2001 FY | -1.99 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 74.798% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 98.647% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 541.583% |
| Wai Yuen Tong Medicine Holdings Limited | 40.88 Million HKD | 11.835% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 169.068% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 88.386% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 154.571% |
| SSY Group Limited | 1.63 Billion HKD | 97.801% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 79.311% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 89.181% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 99.703% |